Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Total Current Liabilities: 2022-2025

Historic Total Current Liabilities for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $24.0 million.

  • Entrada Therapeutics' Total Current Liabilities fell 65.98% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year decrease of 65.98%. This contributed to the annual value of $39.5 million for FY2024, which is 75.14% down from last year.
  • As of Q3 2025, Entrada Therapeutics' Total Current Liabilities stood at $24.0 million, which was up 21.29% from $19.8 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Total Current Liabilities registered a high of $173.9 million during Q1 2024, and its lowest value of $15.4 million during Q1 2022.
  • In the last 3 years, Entrada Therapeutics' Total Current Liabilities had a median value of $85.8 million in 2024 and averaged $93.6 million.
  • Per our database at Business Quant, Entrada Therapeutics' Total Current Liabilities surged by 856.79% in 2023 and then tumbled by 89.40% in 2025.
  • Quarterly analysis of 4 years shows Entrada Therapeutics' Total Current Liabilities stood at $22.0 million in 2022, then surged by 622.72% to $158.8 million in 2023, then plummeted by 75.14% to $39.5 million in 2024, then slumped by 65.98% to $24.0 million in 2025.
  • Its Total Current Liabilities was $24.0 million in Q3 2025, compared to $19.8 million in Q2 2025 and $18.4 million in Q1 2025.